Low-risk PAH Patients May Be Able to Switch from Parenteral to Oral Therapies
Low-risk pulmonary arterial hypertension (PAH) patients may be able to switch from pump-infusion parenteral prostacyclin therapy to more convenient oral therapies, according to the study, “Transition from parenteral to oral treprostinil in pulmonary arterial hypertension,” published in the Journal of Heart and Lung Transplantation. Prostanoids, which include prostaglandins, thromboxanes and prostacyclins,…